CHIC Project Survey: Your Opinion Counts

The EU-funded CHIC project (Computational Horizons In Cancer: Developing Meta- and Hyper-Multiscale Models and Repositories for In Silico Oncology) proposes the development of clinical trial driven tools, services and secure infrastructure that will support the creation of multiscale cancer hypermodels (integrative models). The latter are defined as choreographies of component models, each one describing a biological process at a characteristic spatiotemporal scale, and of relation models/metamodels defining the relations across scales. Integrative models can become component models for other integrative models. The development of a secure hypermodelling infrastructure consisting primarily of a hypermodelling editor and a hypermodelling execution environment is a central generic VPH geared objective of CHIC.

To understand the views, opinions and expectations of citizens and patients about the cancer models/hypermodels a short survey was developed, it will help to optimize research in this area. A short survey video will present the hypermodel developed for nephroblastoma, the most common kidney cancer in children. It will answer the question if preoperative chemotherapy will shrink the tumor before surgery. The prediction of this hypermodel may then be used for helping the physician to apply the best treatment for a patient with nephroblastoma.

The survey video is followed by a short questionnaire consisting of two main parts. The first part is asking demographic questions and the second part is related to the understanding of hypermodels. Your answers are anonymous and the whole survey will take you less than 10 minutes.

You are kindly invited to participate in the hypermodel survey of CHIC project. This survey will help CHIC project consortium to understand the knowledge, expectations and opinions of citizens and patients about the cancer models/hypermodels.

For further information, survey video and survey questions, please visit:
http://www.ehealthserver.com/survey/index.php?r=survey/index&sid=423562

For further information about CHIC project, please visit:
http://www.chic-vph.eu

CHIC project has received funding from the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement No 600841.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...